High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 37, Issue 3-4, 2014, Pages 196-206

  Degerman Gunnarsson, M ^a   Lannfelt, L ^a   Ingelsson, M ^a   Basun, H ^a,b   Kilander, L ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BioArctic Neuroscience   (Sweden)

Author keywords

Alzheimer's disease; Beta amyloid; Cerebrospinal fluid; Dying in severe dementia; Mortality; Phosphorylated tau; Rapid cognitive decline; Tau

Indexed keywords

TAU PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; MEMANTINE; AMYLOID BETA PROTEIN; MAPT PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DYING; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CAUSE OF DEATH; CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; GENOTYPE; HEART FAILURE; PNEUMONIA; PREMATURE MORTALITY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RISK FACTOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TEST; PHOSPHORYLATION; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84885974265     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000355556     Document Type: Article

References (38)

1. Schäufele M, Bickel H, Weyerer S: Predictors of mortality among demented elderly in primary care. Int J Geriatr Psychiatry 1999; 14: 946-956.
2. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I: Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005; 58: 748-757.
3. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW: Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011; 10: 785-796.
4. Holmes C, Lovestone S: Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Aging 2003; 32: 200-204.
5. Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
6. Ravaglia S, Bini P, Sinforiani E, Franciotta D, Zardini E, Tosca P, Moglia A, Costa A: Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. Neurol Sci 2008; 29: 417-423.
7. Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E: Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 2010; 25: 403-410.
8. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM: CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009; 73: 1353-1358.
9. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O: CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010; 11: 1531-1537.
10. Wahlund LO, Blennow K: Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003; 20: 99-102.
11. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH, Alzheimer's Disease Neuroimaging Initiative: The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement 2010; 6: 257-264.
12. Hampel H, Bürger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans AC, Davies P, Möller HJ, Teipel SJ: Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005; 62: 770-773.
13. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P: Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2010; 31: 758-764.
14. Boström F, Hansson O, Blennow K, Gerhardsson L, Lundh T, Minthon L, Zetterberg H, Londos E: Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2009; 28: 314-319.
15. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231-245.
16. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913-4917.
17. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP: Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29: 1143-1159.
18. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4: DSM-IV. Washington, 1994.
20. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
21. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: differences between early-and lateonset AD and stability during the course of disease. Arch Neurol 1999; 56: 673-680.
22. Wallin AK, Blennow K, Andreasen N, Minthon L: CSF biomarkers for Alzheimer's Disease: levels of betaamyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006; 21: 131-138.
23. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O: Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
24. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Alzheimer's Disease Neuroimaging Initiative: Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-toprogression from mild cognitive impairment to Alzheimer's disease. Brain 2010; 133: 3336-3348.
25. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer's Disease Neuroimaging Initiative: MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 28: 294-301.
26. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimäki T, Seubert P: Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry1999; 15: 750-755.
27. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A: Intraindividual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 2007; 12: 255-260. 28.
28. Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK: Longitudinal changes of CSF biomarkers in Alzheimer's disease. J Alzheimers Dis 2011; 25: 583-594.
29. Vlachos GS, Paraskevas GP, Naoumis D, Kapaki E: Cerebrospinal fluid β-amyloid(1-42) correlates with rate of progression in Alzheimer's disease. J Neural Transm 2012; 119: 799-804.
30. Brunnström HR, Englund EM: Cause of death in patients with dementia disorders. Eur J Neurol 2009; 16: 488-492.
31. Jensen M, Basun H, Lannfelt L: Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995; 17: 189-191.
32. Soto ME, Andrieu S, Arbus C, Ceccaldi M, Couratier P, Dantoine T, Dartigues JF, Gillette-Guyonnet S, Nourhashemi F, Ousset PJ, Poncet M, Portet F, Touchon J, Vellas B: Rapid cognitive decline in Alzheimer's disease. Consensus paper. J Nutr Health Aging 2008; 12: 703-713.
33. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, Mohs R, Heyman A: Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease. Arch Neurol 1999; 56: 857-862.
34. Hall CB, Derby C, LeValley A, Katz MJ, Verghese J, Lipton RB: Education delays accelerated decline on a memory test in persons who develop dementia. Neurology 2007; 23: 69: 1657-1664.
35. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA: Modeling Mini Mental State Examination changes in Alzheimer's disease. Stat Med 2000; 19: 1607-1616.
36. Paradise M, Cooper C, Livingston G: Systematic review of the effect of education on survival in Alzheimer's disease. Int Psychogeriatr 2009; 21: 25-32.
37. Allan CL, Ebmeier KP: The influence of ApoE4 on clinical progression of dementia: a meta-analysis. Int J Geriatr Psychiatry 2011; 26: 520-526.
38. Soto C: In vivo spreading of tau pathology. Neuron 2012; 23: 621-623.